Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs – NBC10 Philadelphia
Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug | Investor's Business Daily
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/JO75YOO42VEHBMB23A37IROB7A.jpg "Teva announces Philadelphia-area layoffs of more than 200")
Teva announces Philadelphia-area layoffs of more than 200
Teva Pharmaceutical Stock: Stuck In A Cycle Of Hope And Disappointment | Seeking Alpha
A determined FDA takes down Teva's blockbuster | Evaluate
FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars | Technology
Teva Pharmaceutical's Sales Slump 18% - WSJ
Pharma giant Teva looks to steady ship with new CEO in coming weeks | The Times of Israel
Teva plans to sell Irvine drug plant – Orange County Register
Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters
Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Teva Pharmaceuticals: Value Play or Value Trap? | by Shivam Kollur | Medium
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva's Stock Price Surge Against Its Predictable Woes
 "Zydus faces stiff competition for blockbuster drug in US from Teva Pharma")
Zydus faces stiff competition for blockbuster drug in US from Teva Pharma
Teva Pharmaceuticals appoints Richard Francis CEO | HealthCare Middle East & Africa Magazine
Teva Pharmaceuticals considers laying-off 10,000 workers - The Jerusalem Post
Teva & Barr Get Super-Sized
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters")
Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva Weighs Sale of $2 Billion Active Ingredients Unit - BNN Bloomberg
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
